Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Only 13% of applications were funded last year, STATs Anil Oza writes, with even top-scoring proposals no longer having good odds
Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: The LixiLan-O randomized trial
Safety Profile, Tolerability, and Who Should Consider Retatrutide Retatrutide's most common adverse events are gastrointestinal: nausea, vomiting, and constipation, typically mild to moderate and dose-dependent
Willow scored 97/100 on our Legitimacy & Credentials assessment
10.1158/1535-7163.MCT-08-0250 Mol
US$ 20.29
US$ 26.18
US$ 20.71
US$ 24.05
US$ 28.11
US$ 24.74
US$ 22.42
